GoodRx stock soars after CEO hints at potential TrumpRx partnership
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/27/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
Morgan Stanley Reiterates Equalweight Rating on GoodRx Holdings Inc. (GDRX) Amid Speculation of TrumpRx
October 2, 2025 4:33 AM EDTMorgan Stanley analyst Craig Hettenbach reiterated an Equalweight rating and $5.00 price target on GoodRx Holdings Inc. (NASDAQ: GDRX)
The analyst comments "GDRX traded materially higher today (+19% vs. Russell 2000 +0.2%) on heavy volume (22mn shares or ~10x daily average) following news that the company could potentially partner with TrumpRx. This was discussed during an interview CEO Wendy Barnes had on Fox Business (article). Separately, we view news of an expansion with Kroger (covered by Simeon Gutman) as potentially the more meaningful... More
